𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Introduction: Psychological treatment of the patient with chronic disease

✍ Scribed by David Engle

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
23 KB
Volume
57
Category
Article
ISSN
0021-9762

No coin nor oath required. For personal study only.

✦ Synopsis

There are times when I do not understand why I have this disease. There are times when I feel like giving up-giving into the pain and simply letting it take over not just my body, but my mind as well. But I find I cannot do that. For I am constantly and persistently called out of myself by those around me who seem to feel that my words bring hope into their lives. They do not realize how much their response brings hope back into mine.

Diana Hayes, quoted by Jane Redmont, When in Doubt Sing, p. 155

πŸ“œ SIMILAR VOLUMES

DDB treatment of patients with chronic h
DDB treatment of patients with chronic hepatitis
✍ Roman Huber; Birgit Hockenjos; Hubert E. Blum πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 1 views

We report 13 patients (10 with chronic hepatitis C, 1 with chronic hepatitis B, 2 with nonalcoholic steatohepatitis) with persistently elevated alanine aminotransferase (ALT) levels who were treated with dimethyl-4,4-dimethoxy-5,6,5,6-dimethylenedioxybiphenyl-2,2 dicarboxylate (DDB). ALT rapidly nor

Alemtuzumab as treatment for residual di
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
✍ Susan M. O'Brien; Hagop M. Kantarjian; Deborah A. Thomas; Jorge Cortes; Francis πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti‐CD52 monoclonal antibody, in patients with B‐cell chronic lymphocytic leukemia and residual disease after chemotherapy. ## METHODS Forty‐one patients received alemt